Research
Hormonal
In rodents, resistin administration impairs glucose tolerance and insulin action, while resistin deletion improves insulin sensitivity and glucose homeostasis.
This finding is specific to rodents and does not directly translate to human treatment. Human resistin biology is different, and targeting resistin in humans has not yielded the same clear benefits as in mice.
StrongSupportsVERY_HIGH confidence
Circulating levels of resistin were higher in obese mice, and the administration of recombinant resistin in normal mice impaired glucose tolerance and insulin action. Furthermore, neutralization of resistin with antiresistin antibody improved insulin sensitivity in diet-induced obese mice.
Why this rating
Strong evidence from multiple genetic and pharmacological interventions in rodent models.
Source
Resistin in Rodents and Humans
Hyeong Kyu Park et al. · Diabetes & Metabolism Journal · 2013
DOI 10.4093/dmj.2013.37.6.404
narrative_reviewCited 194×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In rodents, resistin is an adipokine that directly causes insulin resistance and impairs glucose tolerance, whereas in humans, resistin is primarily secreted by macrophages and serves as a marker of inflammation rather than a direct cause of insulin resistance.Good
- Elevated resistin levels are predictive of atherosclerosis, coronary artery disease (CAD), and adverse cardiovascular outcomes in humans, independent of traditional risk factors like CRP.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →